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Introduction
Although the selective serotonin reuptake inhibitor (SSRI) fluoxetine is not universally effective in major depressive disorder (MDD), and in spite of a long latency period for its therapeutic action to take effect, it is widely used in the treatment of MDD. In vivo chronic treatment with fluoxetine leads to upregulation of Ca 2+ -dependent phospholipase A2 (cPLA 2 ) expression in the brain. 1 We have previously reproduced an increased cPLA 2a expression in cultured mouse astrocytes after fluoxetine treatment for 1-4 weeks with a faster response at higher concentrations and an EC 50 of 0.5 µM after 3 weeks of treatment. 2 Paroxetine, citalopram, fluvoxamine and sertraline have identical effects with similar or even greater potency. 3 The upregulation of cPLA 2a in cultured astrocytes is secondary to the ability of acutely administered fluoxetine (and other SSRIs) to directly and spe cifically stimu late the serotonin (5-HT) 2B receptor, [2] [3] [4] [5] whereas well differentiated cultures of astrocytes express no 5-HT transporter. 5 Any 5-HT that might be present in serum added to the culturing medium will be rapidly degraded by a high activity in the cells containing mono amine oxidase (MAO). 6, 7 Another recent in vivo observation was that editing of the Q/R site of the kainate receptor GluK2, the product of Grik2, in the anterior portion of the rat brain was found to be slightly decreased by daily treatment with fluoxetine (10 mg/kg) for 14 days. 8 Messenger RNA expression in GluK2 is edited by adenosine deaminases acting on RNA (ADAR), an enzyme family catalyzing deamination of adenosine to inosine in mRNA, thereby changing the translated protein sequence because inosine is read by the cells as guanosine. 9 There are 3 members in the ADAR family, ADAR1, ADAR2 and ADAR3, 10 all of which are expressed in the brain. 11 The ADAR2 enzyme is found in hippocampal pyramidal neurons, cerebellar Purkinje cells and Bergmann glial cells, all of which have less expression of ADAR1 and ADAR3 than ADAR2. 12 Studies of ADAR2 complementary DNA (cDNA) clones have revealed 4 different isoform mRNAs generated by self-editing and subsequent splicing at 2 different sites, 1 in the deaminase domain and 1 at the 5′-end of the coding sequence. 13 The 4 isoforms have been named ADAR2Sd and ADAR2Ld, which are produced by splicing in the deaminase domain, and ADAR2Sc and ADAR2Lc, which are produced by splicing in the 5′-end of the coding sequence. 14 The different splicing variants and combinations of variants result in the production of proteins with different deaminase activity. [13] [14] [15] The GluK2 receptor has been demonstrated in astrocytes in the rat hippocampus 16 and spinal cord, 17 and S100β-positive astrocytes obtained by fluorescence-activated cell sorting from dissociated rat brain cortical tissue show GluK2 gene expression that is about half as pronounced as in the corresponding neurons. 18 It is unknown whether chronic treatment with fluoxetine affects editing of GluK2 in astrocytes, let alone what effect this has on kainate receptor function.
There is now overwhelming evidence that glutamate homeostasis in the brain plays a major role in mood disorders, 19, 20 especially in the neuronal-glial tripartite synapse. 21 Astrocytes are responsible for the supply of glutamatergic neurons with transmitter glutamate 22 and for the major part of its subsequent clearance from the synaptic cleft. 23 Like neurons, astrocytes are able to release glutamate in a manner stimulated by Ca 2+ , 24, 25 and they express glutamate receptors, which are involved in cross-talk with neuronal synapses and can strengthen synaptic transmission. 22 Specifically regarding GluK2 and GRIK2, patients with different single nucleotide polymorphishms in the DNA of GRIK2 are at an enhanced risk for suicidal ideation during treatment with citalopram or other SSRIs. 26, 27 In rodents in which Grik2 is knocked out, a large number of behavioural traits have been interpreted as equivalents of clinical mania. 28 Major depressive disorder has been found to correlate with decreased GluK2 expression in the entorhinal cortex, 29 but mice in which Grik2 is knocked out display less despair during the forced swimming test and more social interaction, 30, 31 suggesting that the knockout may make them more resistant to depression.
In the present study, we examined • the effects of chronic treatment with fluoxetine on ADAR2
and GluK2 expression and editing in cultured astrocytes and intact brains in mice; • the effect of chronic treatment with fluoxetine on ADAR2 mRNA splicing in cultured astrocytes; • the effect of chronic treatment with fluoxetine on glutamate -induced extracellular signal-regulated kinase (ERK) phosphorylation and [Ca 2+ ] i in cultured astrocytes, both of which were shown to be mediated by GluK2; and
• the effect of 5-HT 2B receptor downregulation with 5-HT 2B receptor small interfering RNA (siRNA) or of ADAR2 knock-down with ADAR2 siRNA on chronic effects of fluoxetine in cultured astrocytes. 
Methods

Animals
Materials
We purchased chemicals for preparation of the medium and most other chemicals, including fluoxetine, NS102 and first antibody raised against β-actin, from Sigma. 
Cell cultures
Primary cultures of mouse astrocytes were prepared as previously described, 32, 33 with minor modifications. The neopallia of the cerebral hemispheres were aseptically isolated, vortexed to dissociate the tissue, filtered through nylon meshes with pore sizes of 80 µm and subsequently 10 µm, diluted in culture medium and planted in Falcon Primaria culture dishes or multiwell plates. The culture medium was a Dulbecco modified Eagle's medium (DMEM) with 7.5 mM of glucose, initially containing 20% horse serum, and the cultures were incubated at 37°C in a humidified atmosphere of CO 2 /air (ratio 5%:95%). The culture medium was exchanged with fresh medium of similar composition on day 3, and subsequently every 3-4 days. From day 3, the serum concentration was reduced to 10%, and after the age of 2 weeks, 0.25 mM dibutyryl cyclic adenosine monophosphate (dBcAMP) was included in the medium. Such cultures are known to be morphologically and functionally differentiated, 34 to express many characteristics of astrocytes in vivo 32 and to be highly enriched (> 95 purity) in glial fibrillary acidic protein (GFAP)-and glutamine synthetase-expressing astrocytes, with the main contaminating cells being macro phages (< 5%) and neurons and oligodendrocytes being absent. 35 
Drug treatment
Chronic drug treatment After 3 weeks of culturing, fluoxetine dissolved in a small volume of phosphate-buffered saline (PBS; 137 mM of NaCl, 2.7 mM of KCl, 10 mM of Na 2 HPO 4 , 2 mM of KH 2 PO 4 , 1 mM of CaCl 2 , 0.5 mM of MgCl 2 and 7.5 mM of glucose, pH 7.4) was added to the cultures to a final concentration of 10 µM. A high concentration was selected to obtain a rapid effect, as previously observed with respect to cPLA 2 expression; 2 controls from the same batches received only PBS.
Acute drug treatment
To determine glutamate effects on ERK 1/2 phosphorylation, we gently removed the culture medium, and the cells were incubated in corresponding medium without serum at 37°C for specified time periods in the absence or presence of 100 µM of L-glutamate. The reaction was stopped by washing with ice-cold PBS containing 7.5 mM of glucose, and the cells were scraped off the dishes and harvested in lysis buffer (50 mM of Hepes, 5 mM of EDTA [the Na + salt], 50 mM of NaCl, 1% Triton-100, 10 mM of β-mercaptoethanol, 1 mM of phenylmethyl sulfonyl fluoride and 1 mM of sodium orthovanadate; pH 7.4).
To determine glutamate effects on intracellular Ca 2+ concentrations, we used a Tecan Infinite M200 microplate analyzer to record fluorescence intensity of fura-2 introduced in astrocyte cultures grown in 24-well plates. For fura-2 loading, we replaced the growth medium with isotonic saline solution (137 mM of NaCl, 5 mM of KCl, 0.44 mM of KH 2 PO 4 , 4 mM of NaHCO 3 , 1.3 mM of CaCl 2 , 0.8 mM of MgSO 4 , and 0.5 mM of MgCl 2 with 10 mM of glucose) containing 5 µM of fura-2 for 30 minutes at 37°C. After washing twice with similar saline, 300 µL of preheated isotonic saline was pipetted into each well, the multiwell plate was reinserted into the microplate analyzer, and readings were made at 340-nm and 380-nm excitations and 510-nm emissions at 24-second intervals for 2 minutes (5 cycles) to establish a baseline, with the wells exposed to illumination from the bottom of the chamber at gain 120. Subsequently, we took the multiwell plate out of the analyzer and added saline solution (control) or a final concentration of 100 µM of glutamate. The multiwell plate was re introduced into the analyzer, and readings continued for another 30 minutes (50 cycles) with similar settings.
Knock-down of the 5-HT 2B receptor, GluK2 and ADAR2
Duplexes of 5-HT 2B receptor siRNA (sense 5′ gggaagcauuuggcagguauu 3′ and antisense 5′ uaccugccaaaugcuucccuuu 3′) 36 and ADAR 2 siRNA (sense 5′ uacaugagugaucguggccuu 3′ and antisense 5′ ggccacgaucacucauguauu 3′) 37 were synthesized by Sangon Co., Ltd. Transfection was performed as previously described. 4 To allow incorporation of siRNAs into astrocytes, 3-week-old astrocytes cultured in Primaria 24-well culture plates were incubated in Dulbecco medium without serum for 24 hours on the day before transfection. Transfection solution contained 2 µL of oligofectamine and 40 µL of Opti-MEM I, and 2.5 µL of siRNA (666 ng) was added to the culture for 8 hours. In siRNA (-) control cultures, transfection solution without siRNA was added. Thereafter, 87.5 µL of DMEM with 37.5 µL serum was added to the cultures. Greatly reduced expression of mRNA and protein of the 5-HT 2B receptor or ADAR2 without effect on the other genes studied was confirmed by Western blotting 3 days after transfection (Fig. 1) , and the mRNA expression of ADAR2 was 100%, 70%, 20% and 20% of control samples in siRNAtreated cells after 8 hours, 1 day, 3 days and 7 days of treatment, respectively (Appendix 1, available at www .cma .ca /jpn). The corresponding effect of siRNA against GluK2 has previously been described and documented. 38 
Experiments in vivo
Male adult CD-1 mice were injected intraperitoneally with a daily dose of fluoxetine (10 mg/kg dissolved in PBS) or PBS for either 3 days or 1 week. They were then decapitated, and cerebral hemispheres minus olfactory bulbs and hippocampi were removed to determine mRNA and protein expression.
Western blotting for ERK, GluK2, 5-HT 2B receptor and ADAR2
Samples containing 50 µg of protein were applied on slab gels of 12% polyacrylamide. After transfer to nitrocellulose membranes, the samples were blocked by 5% skimmed milk powder in tris-buffered saline with Tween 20 (TBS-T) for 2 hours, and the nitrocellulose membranes were incubated with the first antibody, specific to either p-ERK or ERK, GluK2, 5-HT 2B receptor, ADAR2 or β-actin, used for housekeeping, for 1.5 hours at room temperature. After washing, specific binding was detected by goat anti-mouse or goat anti-rabbit horseradish peroxidase-conjugated secondary anti body. We determined ratios between scanned p-ERK 1/2 and scanned ERK 1/2, or between scanned GluK2, 5-HT 2B receptor or ADAR2 protein and β-actin.
Reverse transcription-polymerase chain reaction
For determination by reverse transcription-polymerase chain reaction (RT-PCR) of mRNA expression of the 5-HT 2B receptor, ADAR2, or kainate receptor subtypes, including I/V, Y/C and Q/R edited GluK2, a cell suspension was prepared by discarding the culture medium, adding Trizol to cultures on ice and scraping the cells off the culture dish. The RNA pellet was precipitated with isopropanol, washed with 70% ethanol and dissolved in 10 µL of sterile, distilled water, and an aliquot was used to determine the amount of RNA. 5 Reverse transcription was initiated by a 5-minute incubation at 65°C of 1 µg of RNA extract with random hexamer at a final concentration of 12.5 ng/L and deoxyribonucleoside triphosphates (TaKaRa Bio technology Co.) at a final concentration of 0.5 mM. The mixture was rapidly chilled on ice and briefly Normalized by β-actin 
ARMS-PCR
Reverse (GluK2) 5′ TGTGAAAAACCACCAAATGC 3′
Reverse 5′ TGTGAAAAACCACCAAATGC 3′
spun, and 4 µL of 5X first-strand buffer, 2 µL of 0.1 M dithiotreitol and 1 µL of RNaseOUT Recombinant Ribonuclease Inhibitor (40 U/µL) were added. After the mixture had been incubated at 42°C for 2 minutes, 1 µL (200 U) of SuperScript II (Life Technologies, Invitrogen) was added, and the incubation at 42°C continued for another 50 minutes. Subsequently, the reaction was inactivated by heating to 70°C for 15 minutes, and the mixture was chilled and briefly centrifuged. Polymerase chain reaction amplification was performed in a RoboCycler thermocycler with 0.2 µM of forward and reverse nucleotide sequences (primers), as indicated in Table 1 , and 0.375 units of Taq polymerase. The primer pairs used for quantification of editing at I/V, Y/C and Q/R sites by amplification refractory mutation system (ARMS)-PCR were designed so that the 3′-terminal nucleotide was specific for either adenosine (A) or guanosine (G). 44 When the primer matched the template, amplification occurred normally. However, when the primer mismatched the template, the frequency of extension was very low because Taq polymerase lacks 3′ exonucleotidase activity; consequently, the effective number of sequence copies available for amplification was greatly reduced. 45, 46 In contrast, use of a reverse primer, which contained the appropriate complementary nucleotide sequence, allowed normal amplification. Use of the GluK2 primers allowed amplification of all forms, regardless of whether they were edited or not.
Initially, the template was denatured by heating to 94°C for 2 minutes. This was followed by 30 amplification cycles for GluK2, GluK3, GluK4, GluK5 and TATA-binding protein (TBP); by 40 cycles for GluK1, ADAR2Sd, ADAR2Ld, ADAR2Sc and ADAR2Lc; and by 35 cycles for I/V, Y/C and Q/R nucleotide sequences of GluK2. Each cycle consisted of 3 periods. The first period was for 45 seconds at 94°C. The second was for 45 seconds at 50°C for GluK3; at 58°C for GluK1, GluK4 and GluK5; at 62°C for GluK2 and I/V, Y/C and Q/R editing of GluK2; and at 55°C for ADAR2Sd, ADAR2Ld, ADAR2Sc, ADAR2Lc and TBP. The third was for 90 seconds at 72°C. The final step was extension at 72°C for 10 minutes. The PCR products were separated by 1% agarose gel electrophoresis and captured by FluorChem 5500 (Alpha Innotech Corporation).
Direct PCR sequencing
Polymerase chain reaction amplification was performed with forward and reverse primers for GluK2, as indicated in Table 1 . Complementaty DNA sequencing was carried out by TaKaRa Biotechnology Co., Ltd., and RNA editing efficiencies at I/V, Y/C and Q/R sites were calculated by the peak heights. 47 
Data analysis
We analyzed the differences between multiple groups by 1-way analysis of variance (ANOVA) followed by a Fisher least significant difference multiple comparison test for unequal replications. The level of significance was set at p < 0.05. Least significant difference tests were applied to determine statistical differences in paired groups within multiple experimental groups. We also analyzed the data with a priori contrasts, an analysis without experience hypothesis, and the results were not different after post hoc comparison (results not shown). In the calibration curves, we plotted the scanned intensities as fractions of maximum intensity (ARMS-PCR) or determined ratios between edited and edited plus unedited GluK2 (direct cDNA sequencing) as a function of the ratios in the standards. Correlation analysis was used for the calibration curves of standard samples.
Results
Chronic effect of fluoxetine on mRNA expression of ADAR1 and ADAR2 in cultured astrocytes and intact brains
As shown in Figure 2A , astrocytes express little or no ADAR1 mRNA. The level of ADAR2 mRNA, normalized to TBP, was slightly higher in cerebral tissue than in cultured astrocytes (F 1,4 = 522.2, p = 0.008 ). After 3 days of treatment with 10 µM of fluoxetine, the mRNA expression of ADAR2 was increased to 50% above that in the control group (p = 0.002) in the cultured astrocytes (F 1,4 = 522.2, p = 0.001; Fig. 2B1, B2) . A similar response was seen in the intact brain after 7 days of treatment (F 1,4 = 203.8, p = 0.025; Fig. 2B3, B4 ), but there was no difference in ADAR1 expression between the treatment and control groups (F 1,4 = 0.0, p = 0.89; Fig. 2B5 ). Protein expression of ADAR2 in fluoxetine-treated cells and in the intact brain after fluoxetine treatment was double that in the control group (F 3,10 = 427.4, p = 0.001; Fig. 2C1, C2, C3) . The ADAR2 splicing analysis showed that chronic treatment with fluoxetine for 3 days increased expression of all 4 isoforms in the cultured astrocytes (Fig. 2D1) . When the levels of ADAR2 mRNA in treated cells were normalized to control samples (Fig. 2D2) , the stimulation was higher in ADAR2Ld and ADAR2Sc than in ADAR2Sd and ADAR2Lc (F 3,8 = 246.5, p = 0.001 and F 3,8 = 635.6, p = 0.001, respectively).
Chronic effect of fluoxetine on gene expression of kainate receptor subunits in cultured astrocytes and intact brains
In agreement with previous observations, 38 cultured astrocytes expressed GluK2, GluK3, GluK4 and GluK5 mRNA, but not GluK1 (Fig. 3A1, A2 ), which was also not expressed in the astrocytic cell fraction obtained by fluorescenceactivated cell sorting. 18 Only GluK2 mRNA was upregulated by chronic treatment with fluoxetine (F 7,16 = 50.6, p = 0.005). Protein expression of GluK2 was also increased in fluoxetinetreated cells (F 1,4 = 150.9, p = 0.007; Fig. 3B1, B2 ). The increase of GluK2 protein was more pronounced than that of GluK2 mRNA. In vivo, fluoxetine also enhanced GluK2 mRNA ( 
Chronic efffect of fluoxetine on glutamate-induced ERK phosphorylation and increase of intracellular Ca 2+ concentration in cultured astrocytes
As previously reported, 38 20 minutes of treatment with 100 µM of glutamate induced an increase of ERK 1/2 phosphorylation in cultured astrocytes with no difference in total amount of ERK 1/2 (p-ERK 1 : F 7,16 = 189.0, p = 0.011; p-ERK 2 : F 7,16 = 294.3, p = 0.002; Fig. 4A1, A2, A3 ). Chronic treatment with fluoxetine for 3 days eliminated the effect on ERK 1/2 phosphorylation by glutamate (Fig. 4A1, A2, A3 ). The fact that the glutamate effect in untreated cultures was induced by GluK2 receptor activity was confirmed both by an inhibitory effect of NS102, a specific antagonist of GluK1 and GluK2 48 ( Fig. 4A1, A2, A3) , and by the ability of knockdown of expression of GluK2 mRNA and protein by 3 days of treatment with specific siRNA 38 to abolish the effect of glutamate (p-ERK 1 : F 3,8 = 45.0, p = 0.023; p-ERK 2 : F 3,8 = 140.2, p = 0.002; Fig. 4B1, B2, B3 ). The transfection solution alone without siRNA had no effect (results not shown). As shown in Figure 4C , treatment with 100 µM of glutamate also caused a significant increase of intracellular Ca 2+ concentration ([Ca 2+ ] i ), amounting to a significant 3-to 4-fold increase from the control value, lasting for at least 25 minutes. Three days of treatment with fluoxetine also abolished this effect of glutamate (5 min after drug treatment: 
Effect of 5-HT 2B receptor siRNA on chronic effects of fluoxetine in cultured astrocytes
In cultured astrocytes with knock-down of the 5-HT 2B receptor ( Fig. 1 ), chronic treatment with fluoxetine for 3 days had lost its effect on mRNA (Fig. 5A1-4) and protein ( Fig. 5B1-4 ) expression of ADAR2 (Fig. 5A1, A2 The magnitude of the response to glutamate in control cells and fluoxetine-exposed cells that had been treated with 5-HT 2B receptor siRNA were virtually identical.
Effect of ADAR2 siRNA on chronic effects of fluoxetine in cultured astrocytes
In cultured astrocytes with ADAR2 knock-down (Fig. 1 . We scanned the band intensities of these standard mixtures (left part of the gels in Fig. 7 and 8A1, B1 and C1) and expressed them as fractions of maximum intensity. These fractions were then plotted as functions of the ratios between edited and the sum of edited plus unedited GluK2 ( Fig. 7 and 8A2, B2 and C2). The ratios between the edited, G-containing (V, C and R) and unedited, A-containing (I, Y and Q) isoforms in the PCR products obtained from the cultured astrocytes under control conditions and in fluoxetine-treated cultures (Fig. 7A2, B2 and C2, open and closed triangles and diamonds) or obtained from an intact brain (Fig. 8A2, B2 and C2, open triangle and diamond) were then read from the respective calibration curves. In control cells (open triangles), the frequency of editing was about 80% at site I/V (Fig. 7A2) , > 70% at site Y/C (Fig. 7B2) and about 85% at site Q/R (Fig. 7C2) . However, in cells treated chronically with fluoxetine for 3 days (open diamonds), the frequency of editing was increased to > 90% at site I/V ( Virtually identical results for editing under control conditions and after fluoxetine treatment were obtained by cDNA sequencing performed by TaKaRa Biotechnology Co., Ltd. (Table 2 ).
Summary of interactions between the 5-HT 2B receptor, ADAR2 and GluK2 expression and editing
As illustrated in Figure 9 , chronic administration of fluoxetine, a specific 5-HT 2B agonist, resulted in upregulation of mRNA and protein expression of GluK2 in cultured and in vivo astrocytes (Fig. 9, white arrowhead) . This treatment also upregulated ADAR2 (Fig. 9, double arrowhead) , an adenosine deaminase that acts on RNA, catalyzing mRNA editing. In the cultured cells, the upregulation of GluK2 was prevented by siRNA directed either against the 5-HT 2B receptor or ADAR2 (Fig. 9, grey lines) . Under control conditions, editing of all 3 GluK2 editing sites was extensive both in cultured astrocytes and in intact brains, and editing was further enhanced by treatment with fluoxetine ( Fig. 9, bold arrow) . In the cultured astrocytes, the enhanced editing was abolished by 5-HT 2B receptor or ADAR2 siRNA (Fig. 9, grey lines) . The increased editing resulted in abolishment of glutamatemediated increases in [Ca 2+ ] i and phosphorylation of ERK 1/2 in cultured astrocytes. The abolished effect of glutamate on ERK 1/2 induced by fluoxetine and the enhanced editing were both prevented by knock-down of the 5-HT 2B receptor or ADAR2 with siRNAs, suggesting important interactions between fluoxetine, astrocytic 5-HT 2B and GluK2 receptors, GluK2 receptor editing and glutamatergic brain function.
Discussion
The present study has shown that chronic treatment with fluoxetine upregulates the expression and editing of GluK2, and that the increased editing results in abolishment of the ability of 100 µM of glutamate to increase [Ca 2+ ] i and phosphorylation of ERK 1/2 , a process known to depend on increased [Ca 2+ ] i . 4 It has been reported that activation of metabotropic glutamate receptors increases [Ca 2+ ] in astrocytes, 49, 50 and it cannot be excluded that simultaneous activation of a metab otropic glutamate receptor and GluK2 is required for response. The abolishment of this response in cultured astrocytes treated with fluoxetine demonstrated in the present study does not equal receptor downregulation, since Na + permeability is likely to be maintained and probably even enhanced owing to the upregulation of GluK2 expression.
The increased editing in in vivo brain cortical tissue observed in our study is in disagreement with the results of Barbon and colleagues, 51 who found a slight decrease in editing in cortical tissue; however, these authors studied the entire anterior pole of the brain, including white matter, they used rats, and their medication protocol was different. In addition, it has been reported that editing of other receptors was modulated both by the genetic background and the behavioural state of the animals. 52 The reliability of our observation of increased editing is supported by the abolishment of glutamate effects on [Ca 2+ ] i , since editing of the Q/R site is known to reduce Ca 2+ permeability of GluK2. 48, 53, 54 Moreover, it has been reported that a mutant mouse with greatly reduced Q/R site editing showed a kainate-induced increase in [Ca 2+ ] i in cultured hippocampal neurons, whereas there was no such effect in corresponding neurons from wild-type animals. 53 The extent of GluK2 editing of the Q/R site that we observed in the cerebral tissue of control animals (84%) was consistent with previously reported values of 80%-90% in rodent brains. 51, [55] [56] [57] The tendency toward slightly greater editing at the Q/R site than at the 2 other sites confirms the previous results of Barbon and colleagues. 51 The editing in the cultured astrocytes was much more extensive than previously reported, [57] [58] [59] perhaps reflecting the differentiation induced by dBcAMP.
The abolishment of fluoxetine effects on upregulation of gene expression of ADAR2 and GluK2 in cultured astrocytes with 5-HT 2B receptor knockout was consistent with our previous findings that acute exposure to fluoxetine induced no ERK phosphorylation in cultured astrocytes treated with siRNA against the 5-HT 2B receptor 4 and that chronic exposure to fluoxetine failed to upregulate cPLA 2 expression in such cells. 2 The lack of upregulation of GluK2 expression both in ADAR-reduced cells and in 5-HT 2B receptor-reduced cells suggests that the upregulation was a response to the editing and its functional consequences.
The observation that cultured astrocytes expressed ADAR2, but little ADAR1, and that chronic treatment with fluoxetine caused upregulation of ADAR2 expression, but had no effect on ADAR1 in either cultured or in vivo astrocytes suggests that the increase of ADAR2 activity may be the underlying mechanism of drug action on RNA editing of GluK2. The level of expression of ADAR2 does not correlate directly with the enzyme activity alone, but also depends on isoform distribution. 13, 14, 60 We found that fluoxetine upregulated all 4 isoforms, although it upregulated Ld to a larger extent than the Sd isoform and Sc to a larger extent than the Lc isoform. High levels of expression of both the Sd and Sc isoforms indicate an increase of editing activity, at least of the GluK2 Q/R site in hypothalamic tuberomamillary neurons. 14 Thus, fluoxetine not only upregulates the expression of ADAR2 but also enhances its editing activity. The signalling events linking 5-HT 2B activation with upregulation of ADAR2 are unknown, but we have previously shown that upregulation of cPLA 2 was dependent on metalloproteinase-mediated release of an epidermal growth factor (EGF) receptor agonist and subsequent stimulation of the EGF receptor by this agonist, leading to ERK 1/2 activation and entry of p-ERK 1/2 into the nucleus. 4, 38 The implication of GluK2 editing for brain function is largely unknown. However, although mice deficient in GluK2 expression do not necessarily behave like animals with abolished Ca 2+ response due to increased editing, it may be of interest that GluK2-deficient transgenic mice (lacking J Psychiatry Neurosci 2011;36(5) , an effect that is prevented (grey lines) by small interfering RNA (siRNA) against the 5-HT 2B receptor (si5-HT 2B R). Fluoxetine also increases mRNA and protein expression of GluK2 (white arrowhead), an effect that is inhibited by both si5-HT 2B R and siADAR2 (grey lines), indicating that it is dependent upon ADAR upregulation and perhaps also ADAR2-mediated upregulation of GluK2 editing (bold arrow), which also is inhibited by siADAR2 (the experiments cannot distinguish between these 2 possibilities, indicated by the 2 dotted arrows). As a result of the editing of glutamate-mediated GluK2, GluK2-dependent ERK phosphor ylation is inhibited, an effect that is abolished by si5-HT 2B R or siADAR2, which prevent fluoxetine-induced GluK2 editing. both neuronal and astrocytic GluK2) show a large and statistically significant reduction in long-term fear memory and show that synaptic potentation is reduced. 61 Conversely, in mutant animals deficient in Q/R site editing, Vissel and colleagues 54 found that N-methyl-D-aspartate (NMDA)-independent longterm potentiation could be induced in the medial perforant path-dentate gyrus synapse, which was not possible in wildtype animals. The mutant mice were also more sensitive to kainate-induced seizures. 54 Behavioural tests showed no significant abnormalities, but nonsignificant increases in the startle response to acoustic stimulation and decreases in open field activity might suggest increased anxiety or emotionality. Accordingly, blunted GluK2 receptor function may represent a decrease in excitatory brain activity, which might at least partly be due to an effect on astrocytic receptors.
There is substantial evidence of a decrease in astrocytic glutamate transporters in the frontal cortex 62, 63 and locus coeruleus 64 associated with MDD. The localization to the locus coeruleus is important because astrocytes constitute an important target for the adrenergic locus coeruleus signalling 65 and because abnormalities were also found in several astrocyte-specific locus coeruleus genes. There is also evi dence that a decrease in NMDA-mediated signalling has an antidepressant effect, 66 but, to our knowledge, the present study is the first to suggest a similar effect by reduction of kainate-mediated signalling and especially astrocytic kainatemediated signalling. However, in view of the role of astrocytic Ca 2+ transients for astrocytic modulation of neuronal activity, 67, 68 regulation of astrocytic Ca 2+ responses by downregulation of an astrocytic ionotropic receptor may yield a more selective response.
Limitations
Limitations of the study include the use of cells developing in cultures, which often differ from in vivo astrocytes. 18 However, the routine administration of dBcAMP is intended to replace differentiating noradrenergic signals, which the cultured cells do not receive because they are harvested before locus coeruleus fibres reach the neopallium, and it makes the cultured astrocytes much more similar to their in vivo counterparts. 34 In the cells treated with dBcAMP, the level of expression of the 5-HT 2B receptor was increased, 5 but the treatment had no effect on expression of ADAR2 and GluK2 (B. Li and L. Peng, unpublished results, 2010). Nevertheless, it remains a goal to confirm key aspects of this study in vivo with subsequent fluorescence-activated cell sorting to obtain freshly isolated astrocytes and neurons.
Conclusion
Chronic administration of fluoxetine resulted in upregulation of the expression of GluK2 in cultured astrocytes and the intact brain. This treatment also upregulated ADAR2, and the upregulation of GluK2 was prevented by siRNA directed either against the 5-HT 2B receptor or ADAR2. Under control conditions, editing of all 3 GluK2 editing sites was extensive both in cultured astrocytes and the intact brain, and it was further enhanced by fluoxetine treatment. In the cultured astrocytes, the enhanced editing was abolished by the siRNA treatment. The increased editing resulted in abolishment of glutamate-mediated increases in [Ca 2+ ] i and phosphorylation of ERK 1/2 . In addition, ADAR2 self-edited and thereby probably enhanced its enzymatic activity.
